Researcher Awarded $1.2M To Continue Sepsis Research

Professor Haichao Wang, PhD

Feinstein Institute for Medical Research Professor, PhD, recently received a $1.2 million grant from the National Institutes of Health’s (NIH) National Institute for General Medical Sciences (NIGMS) to continue his search to identify different proteins associated with sepsis, which could lead to a targeted treatment for the condition. This is the fourth NIH grant since 2002 that Wang has received for sepsis research.

Sepsis affects more than one million Americans annually—up to 50 percent of whom die. The condition is a life-threatening, body-wide immune system reaction to an infection, which commonly presents symptoms such as fever, swelling, pain, fast heart rate, difficulty breathing, chills and disorientation. While recent research has pinpointed warning signs to identify and protocols to help with the different sepsis symptoms, more understanding of the biological mechanisms is required to develop a treatment for the condition. Fluids and antibiotics are currently administered to reduce the inflammation in sepsis patients, but it remains unclear what the root cause of inflammation may be.

“Our work shows that TTN decreases the amount of HMGB1 released by immune cells,” said Wang. “With this continued support from the NIH/NIGMS, we hope to fully understand the relationship between TTN and HMGB1 in order to develop possible therapies for sepsis.”
Previous research conducted by Wang, along with Chief Scientific Officer of the Feinstein Institute Dr. Ping Wang and Feinstein president and CEO Dr. Kevin J. Tracey, found that the protein HMGB1 released by the cells in our immune system accelerates the dysregulated inflammation associated with sepsis. In his current study, Wang believes his research team has identified a particular protein called tetranectin (TTN), which could reduce the amount of HMGB1 released in sepsis patients.

Sepsis or septicaemia is a life-threatening illness. Presence of numerous bacteria in the blood, causes the body to respond in organ dysfunction.

“Sepsis is a lethal and common syndrome, and the available treatments are inadequate—research into this problem is in the national interest,” said Tracey. “The NIH’s continued support of Dr. Haichao Wang is evidence of the outstanding contributions he has made to understanding this deadly problem.”

Wang and his team will be examining the levels of TTN and HMGB1 in mice to map the different ways TTN and HMGB1 are interacting to increase or reduce the inflammation related to sepsis.

Anton Media Staff
In addition to its arts and entertainment publication Long Island Weekly, Anton Media Group publishes 16 community newspapers, several magazines, specialty publications and websites. With brands dating back to 1877, Anton has a commitment to deliver trusted and relevant content to the communities it serves.

Leave a Reply

Discover

Sponsor

Latest

Calendar of Events From November 26 to December 5

Here is a selection of events happening in the Long Island Weekly coverage area. Friday, November 26 Peter White Christmas At 8 p.m. at the Madison Theater...

Unraveling Current Events With The Drive-By Truckers

If ever there was a musical prism through which the divisive social and political events of the past five years could be viewed from...

Drive-By Trucker Patterson Hood’s Fave Southern Acts

In the world of Americana, you’d be hard pressed to find an act as politically outspoken as The Drive-By Truckers (DBT). With origins in...

Thanksgiving Greetings From The Red Cross

During this season of gratitude, I want to offer my heartfelt thanks to all our neighbors who make helping others a priority in their...

Michael Draws, Jonathan Graziosi Serve Those Who Served

In recognition of Veterans Day (Nov. 11), a group of PSEG Long Island co-workers took time last week to make some outdoor space more...

Get Updates Via Email

Enter your email to be updated with all the latest news and special announcements.

Professor Haichao Wang, PhD
Feinstein Institute for Medical Research Professor, PhD, recently received a $1.2 million grant from the National Institutes of Health’s (NIH) National Institute for General Medical Sciences (NIGMS) to continue his search to identify different proteins associated with sepsis, which could lead to a targeted treatment for the condition. This is the fourth NIH grant since 2002 that Wang has received for sepsis research. Sepsis affects more than one million Americans annually—up to 50 percent of whom die. The condition is a life-threatening, body-wide immune system reaction to an infection, which commonly presents symptoms such as fever, swelling, pain, fast heart rate, difficulty breathing, chills and disorientation. While recent research has pinpointed warning signs to identify and protocols to help with the different sepsis symptoms, more understanding of the biological mechanisms is required to develop a treatment for the condition. Fluids and antibiotics are currently administered to reduce the inflammation in sepsis patients, but it remains unclear what the root cause of inflammation may be. “Our work shows that TTN decreases the amount of HMGB1 released by immune cells,” said Wang. “With this continued support from the NIH/NIGMS, we hope to fully understand the relationship between TTN and HMGB1 in order to develop possible therapies for sepsis.” Previous research conducted by Wang, along with Chief Scientific Officer of the Feinstein Institute Dr. Ping Wang and Feinstein president and CEO Dr. Kevin J. Tracey, found that the protein HMGB1 released by the cells in our immune system accelerates the dysregulated inflammation associated with sepsis. In his current study, Wang believes his research team has identified a particular protein called tetranectin (TTN), which could reduce the amount of HMGB1 released in sepsis patients.
Sepsis or septicaemia is a life-threatening illness. Presence of numerous bacteria in the blood, causes the body to respond in organ dysfunction.
“Sepsis is a lethal and common syndrome, and the available treatments are inadequate—research into this problem is in the national interest,” said Tracey. “The NIH’s continued support of Dr. Haichao Wang is evidence of the outstanding contributions he has made to understanding this deadly problem.” Wang and his team will be examining the levels of TTN and HMGB1 in mice to map the different ways TTN and HMGB1 are interacting to increase or reduce the inflammation related to sepsis.
x